Literature DB >> 8743633

Changes in sensitivity to nicotine and brain nicotinic receptors following chronic nicotine and corticosterone treatments in mice.

S F Robinson1, E U Grun, J R Pauly, A C Collins.   

Abstract

Chronic nicotine treatment often results in tolerance to nicotine as well as increases in brain [3H]-nicotine binding and [125l]-alpha-bungarotoxin (alpha-BTX) binding. Chronic corticosterone (CCS) treatment also produces tolerance to nicotine, but it does not change [3H]-nicotine binding; decreases in alpha-BTX binding are observed, which suggests that tolerance to nicotine may be related to decreases in the number of this nicotinic receptor subtype. In the studies reported here, C57BL/6 mice were implanted subcutaneously with cholesterol or 60% CCS/40% cholesterol-containing pellets and were infused continuously with saline (control) or nicotine for a total of 9 days. Effects of acute nicotine challenge on Y-maze crossing and rearing activities, heart rate, and body temperature were measured. Both chronic nicotine and CCS treatment resulted in tolerance to nicotine for all of the measures, and some evidence for additivity was seen in the animals that were cotreated with CCS and nicotine. Chronic nicotine infusion increased brain nicotine binding and CCS treatment reduced alpha-BTX binding. Decreases in alpha-BTX binding were not detected in the cotreated animals. The latter finding argues that changes in alpha-BTX binding are not reliable predictors of or a cause of tolerance to nicotine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8743633     DOI: 10.1016/0091-3057(95)02281-3

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  8 in total

Review 1.  Tobacco addiction and the dysregulation of brain stress systems.

Authors:  Adrie W Bruijnzeel
Journal:  Neurosci Biobehav Rev       Date:  2012-03-03       Impact factor: 8.989

Review 2.  Mouse models for studying genetic influences on factors determining smoking cessation success in humans.

Authors:  F Scott Hall; Athina Markou; Edward D Levin; George R Uhl
Journal:  Ann N Y Acad Sci       Date:  2012-02       Impact factor: 5.691

3.  FKBP5 variation is associated with the acute and chronic effects of nicotine.

Authors:  K P Jensen; A I Herman; M E Morean; H R Kranzler; J Gelernter; M Sofuoglu
Journal:  Pharmacogenomics J       Date:  2014-12-23       Impact factor: 3.550

4.  Regulation of the nicotinic receptor alpha7 subunit by chronic stress and corticosteroids.

Authors:  Richard G Hunter; Erik B Bloss; Katharine J McCarthy; Bruce S McEwen
Journal:  Brain Res       Date:  2010-02-11       Impact factor: 3.252

5.  Nicotine physical dependence and tolerance in the mouse following chronic oral administration.

Authors:  Sheri D Grabus; Billy R Martin; Angela M Batman; Rachel F Tyndale; Edward Sellers; M Imad Damaj
Journal:  Psychopharmacology (Berl)       Date:  2004-09-10       Impact factor: 4.530

6.  Bupropion and its main metabolite reverse nicotine chronic tolerance in the mouse.

Authors:  Sheri D Grabus; Frank Ivy Carroll; Mohamad Imad Damaj
Journal:  Nicotine Tob Res       Date:  2012-05-15       Impact factor: 4.244

7.  Crucial role of alpha4 and alpha6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration.

Authors:  S Pons; L Fattore; G Cossu; S Tolu; E Porcu; J M McIntosh; J P Changeux; U Maskos; W Fratta
Journal:  J Neurosci       Date:  2008-11-19       Impact factor: 6.167

Review 8.  Guidelines on nicotine dose selection for in vivo research.

Authors:  Shannon G Matta; David J Balfour; Neal L Benowitz; R Thomas Boyd; Jerry J Buccafusco; Anthony R Caggiula; Caroline R Craig; Allan C Collins; M Imad Damaj; Eric C Donny; Phillip S Gardiner; Sharon R Grady; Ulrike Heberlein; Sherry S Leonard; Edward D Levin; Ronald J Lukas; Athina Markou; Michael J Marks; Sarah E McCallum; Neeraja Parameswaran; Kenneth A Perkins; Marina R Picciotto; Maryka Quik; Jed E Rose; Adrian Rothenfluh; William R Schafer; Ian P Stolerman; Rachel F Tyndale; Jeanne M Wehner; Jeffrey M Zirger
Journal:  Psychopharmacology (Berl)       Date:  2006-08-09       Impact factor: 4.530

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.